Reported Friday, Regeneron Fianlimab Combination Fails To Reach Statistical Significance In First-Line Unresectable Or Metastatic Melanoma Phase 3 Trial

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)

A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy

Phase 3 head-to-head trial of the high-dose fianlimab combination versus Opdualag® (nivolumab and relatlimab-rmbw) is ongoing

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.